bioAffinity Technologies, Inc. — Director's Dealing 2023

Sep 25, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2023-09-18

Reporting Person: Reveles Xavier Trinidad (Chief Operating Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3619	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.70	2028-05-07	Common Stock (2857)		Direct
Stock Option (Right to Buy)	$7.70	2029-02-25	Common stock (1428)		Direct
Stock Option (Right to Buy)	$7.70	2030-02-05	Common Stock (1428)		Direct
Stock Option (Right to Buy)	$7.70	2031-07-26	Common Stock (2142)		Direct

Footnotes

F1: This restricted stock award was granted on November 17, 2022 and vest pro rata monthly over one year.

F2: This stock option is fully vested and reflects a stock split that occurred on June 23, 2022.